Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients ...
News posting on June 13, 2008 | Related to Transave
Transave, Inc., today reported positive results from a Phase II clinical trial on its lead investigational drug, Arikace . The compound is being developed for the treatment of cystic fibrosis patients who have lung infections due to the bacterium Pseudomonas aeruginosa.
Source: PR Newswire via Yahoo! Finance
